Involvement of Pollutants in Atopic Dermatitis and Psoriasis

NCT06213688 | Unknown

• 1 other identifier: RCAPHM23_0328
• Study Type: interventional
• Target: 64
• Locations: 0 countries
• Sites: N/A

Brief Summary

Introduction Pollution is a significant public health issue. Research has shown a positive correlation between air pollution and chronic inflammatory dermatoses, including psoriasis and eczema. The incidence of these diseases has been steadily increasing since the beginning of industrialization. The mechanism behind this association involves the activation of the aromatic hydrocarbon receptor (AhR). The aryl hydrocarbon receptor (AhR) plays a role in regulating the balance between T helper 17 (TH17) and regulatory T cells (TREG), as well as in generating oxidative stress and producing pro-inflammatory cytokines. Studies in cultured keratinocytes have shown that a non-competitive antagonist that modulates AhR activity can reduce cutaneous inflammatory processes induced by polycyclic aromatic hydrocarbons (PAHs). Objectives: It has been suggested that activation of the AhR by PAHs and dioxins may be related to the pathogenesis of atopic dermatitis and psoriasis. The main objective is to compare the levels of AhR pathway activation markers between cases and controls. Secondary objectives include correlating environmental exposure to AhR ligands with disease severity in patients. Finally, we will compare the expression of inflammatory and AhR activation markers in cultured peripheral blood mononuclear cells (PBMCs) after in vitro stimulation with benzo(a)pyrene. Material and methods: The study will measure exposure to pollutants by determining blood dioxins and urinary PAH metabolites. Pro-inflammatory cytokines IL1β, TNFα, IL23, IL17 and IFNγ and Malondialdehyde (MDA) serum concentrations will be measured by ELISA. The TREG and TH17 lymphocyte population ratio will be evaluated by flow cytometry on isolated PBMCs. Additionally, the level of expression of CYP 1A1 and 1B1, pollutant-metabolizing enzymes induced by AhR, will be assessed on isolated PBMCs. The expression levels of the AhR and NfkB active fractions will be determined by immunofluorescence. Subsequently, levels of AhR activation markers will be compared after stimulation of PBMCs with benzo(a)pyrene.

Conditions

Psoriasis; Atopic Dermatitis

Keywords

Atopic dermatitis; Psoriasis; Aryl hydrocarbon receptor; Dioxins; Polycyclic aromatic hydrocarbons; Pollution

Outcome Measures

Primary Outcomes (1)

• Determination of CYP 1A1/1B1 in PBMCs

  The expression of CYP1A1 and CYP1B1 in PBMCs in ng/mL is used as primary endpoint;

  Inclusion

Study Arms (2)

Cases

OTHER

Patients with atopic dermatitis or psoriasis

Other: blood sampling; Other: urine sampling

Controls

OTHER

Patients have consulted or been hospitalized for dermatological reasons without psoriasis or atopic dermatitis

Other: blood sampling; Other: urine sampling

Interventions

blood sampling OTHER

blood sampling at inclusion

Cases; Controls

urine sampling OTHER

urine sampling at inclusion

Cases; Controls

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged 18 to 85.
• The study's participants possess the capacity to comprehend the research.
• Patients have consulted or been hospitalized for dermatological reasons
• Patients undergo biological monitoring as part of their routine care.
• Having psoriasis or atopic dermatitis for more than 6 weeks (cases)

You may not qualify if:

• Active smoking or less than 3 months since quitting
• Pregnancy
• Person in an emergency situation, adult subject to a legal protection measure (adult under guardianship, curatorship or safeguard of justice).
• Non-affiliation with a social security scheme (beneficiary or dependent).
• Subjects with a history of autoimmune diseases (controls)

Sponsors & Collaborators

• Assistance Publique Hopitaux De Marseille: lead
• ALPHENYX: collaborator
• Aix Marseille Université: collaborator

MeSH Terms

Conditions

Psoriasis; Dermatitis, Atopic

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• Richard Marie-Aleth

  AP-HM

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Anaïs Maugard

CONTACT

0491435186; anais.maugard@ap-hm.fr

DRCI APHM

CONTACT

promotion.interne@ap-hm.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 10, 2024
• First Posted: January 19, 2024
• Study Start: March 1, 2024
• Primary Completion: March 1, 2025
• Study Completion: March 1, 2025
• Last Updated: January 19, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share